author-photo

Patrick J. Roberts

Research Triangle Park
University of North Carolina at Chapel Hill

61

Papers

4457

Citations

Citation Trend

Filter By

Papers (48) Sort By

Journal Conference Others

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.

2021 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (2)
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (12)
Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treatKRAS-mutant pancreatic cancer

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (42)
Abstract 4415: CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Abstract 4732: CDK4/6 inhibition with lerociclib (G1T38) enhances response to PI3K or ERK inhibitors in high-throughput, ex vivo pancreatic PDX screens

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
1671PTrilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1752: Transient exposure of trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates to promote a pro-inflammatory tumor microenvironment

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.

2017 Science Translational Medicine
Show All
- Source
- Cite
- Save
Citations (64)